Targets › TNF
27 programs from 26 companies in 125 trials: 58 Phase 2, 34 Phase 4, 18 Phase 1, 15 Phase 3; Immunology, Oncology, Genitourinary; next expected readout Nov 2026.
Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR, activating the tumor necrosis factor-mediated (TNF) signaling pathway. The TNF signaling pathway acts as a master regulator of the immune system, which either (1) promotes cell survival and inflammation by activating the canonical NF-kappa-B pathway or (2) trigger programmed cell death (apoptosis and necroptosis). (UniProt, P01375)
Open in Phaseline: the race on TNF, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Taizhou Mabtech Pharmaceutical | Infliximab TNF-alpha inhibitor | TNF | Phase 4 | Crohn Disease; Inflammatory Bowel Diseases; Ulcerative Colitis; Schizophrenia … | Nov 2026 |
| University of Pennsylvania | 2-[18F]-FA Voltage-gated calcium channel modulator | CHRNA4, OPRK1, OPRD1, OPRM1, UL51, ADRA2A, ADRA2C, ADRA2B, Ion channels, CACNB4, CACNB2, CACNB1, CACNB3, TNF, SLC6A4, HTR2A, HTR2C, FKBP1A, CD86, CD80, PDE4A, PDE4D, PDE4B, PDE4C, PDE3A, CHRNB2, STN | Phase 4 | Alcohol Use Disorder; Acute Kidney Injury; Insomnia; Giant Cell Arteritis … | Nov 2026 |
| University of Calgary | CBD 100 mg OD Interleukin-23 inhibitor | CNR1, PLAT, IL12B, IL23A, ADRB2, HTR2A, NR3C1, TNF, PTGS2, PTGS1 | Phase 4 | Copd; Ehlers-Danlos Syndrome; Crohn Disease; Vasovagal Syncope … | Dec 2026 |
| Odense University Hospital | Capsule FMT Amiloride-sensitive sodium channel, ENaC blocker | GLP1R, ATP4A, ATP4B, CTLA4, FKBP1A, TNF, PDCD1, SCNN1A, SCNN1B, SCNN1G | Phase 4 | Gastroesophageal Reflux; Colitis; Chronic Kidney Disease(CKD); Postmenopausal Women … | Dec 2026 |
| Nanfang Hospital, Southern Medical University | Etanercept TNF-alpha inhibitor | TNF | Phase 4 | Spondyloarthritis (SpA) | Mar 2027 |
| Chia Tai Tianqing Pharmaceutical Group | Adalimumab TNF-alpha inhibitor | TNF | Phase 4 | Adult Non-infectious Uveitis; Crohn's Disease; Children Aged 6 Years and Above With Moderate - to - Severe Active Crohn's Disease; Takayasu Arteritis … | Feb 2028 |
| Connecticut Children's Medical Center | Anti-TNF therapy (Remicade, Inflectra, Renflexis, Avsola, Humira, Amgevita, Huli TNF inhibitor | TNF | Phase 4 | Crohn Disease | Jul 2028 |
| University Hospital, Strasbourg, France | Certolizumab Pegol TNF-alpha inhibitor | TNF | Phase 4 | Rheumatoid Arthritis | Mar 2029 |
| University Hospital, Strasbourg, France | etanercept TNF-alpha inhibitor | TNF | Phase 4 | Rheumatoid Arthritis | Mar 2029 |
| London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Etanercept TNF-alpha inhibitor | TNF | Phase 4 | Rheumatoid Arthritis | – |
| Johnson & Johnson (Janssen) | Golimumab TNF-alpha inhibitor | TNF | Phase 3 | Colitis, Ulcerative; Rheumatoid Arthritis; Peripheral Spondyloarthritis | Feb 2027 |
| Philogen | L19TNF L19-targeting TNF fusion protein | TNF | Phase 3 | Malignant Melanoma; Glioblastoma; Melanoma Stage III; Locally Advanced Basal Cell Carcinoma … | Jul 2028 |
| Assistance Publique - Hôpitaux de Paris | Certolizumab Pegol TNF-alpha inhibitor | TNF | Phase 3 | Recurrent Unexplained Implantation Failure | Apr 2029 |
| mAbxience Research | MB04 TNF-alpha inhibitor | TNF | Phase 3 | Rheumatoid Arthritis (RA) | – |
| Wayne State University | Etanercept TNF-alpha inhibitor | TNF | Phase 2 | Tinnitus, Noise Induced | Dec 2026 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Pirfenidone Anti-fibrotic agent with anti-inflammatory properties | TNF, TGF-BETA | Phase 2 | To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma | Dec 2026 |
| Sun Yat-sen University | rmhTNF-NC Recombinant human tumor necrosis factor | TNF | Phase 2 | Malignant Ascites | Dec 2026 |
| Teva Branded Pharmaceutical Products R&D | TEV-48574 TNF-α antagonist monoclonal antibody (duvakitug) | TNF | Phase 2 | Crohn Disease | Jan 2027 |
| Sir Run Run Shaw Hospital | Icaritin Downregulates TNF-α, IL-6, and PD-L1 expression; reduces MDSC proportion to modulate tumor | TNF, IL6, PDCD1LG1 | Phase 2 | Advanced Pancreatic Ductal Adenocarcinoma | Apr 2027 |
| David Ware Branch | Certolizumab Pegol TNF-alpha inhibitor | TNF | Phase 2 | High Risk Pregnancy | Dec 2027 |
| Chiesi Farmaceutici | CHF10067 (Zampilimab) TNF-α inhibitor monoclonal antibody | TNF | Phase 2 | Idiopathic Pulmonary Fibrosis | Jun 2028 |
| National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland | Etanercept TNF-alpha inhibitor | TNF | Phase 2 | SAPHO Syndrome | Oct 2028 |
| Memorial Sloan Kettering Cancer Center | Certolizumab Pegol TNF-alpha inhibitor | TNF | Phase 2 | Lung Cancer | – |
| Prestige Biopharma | Adalimumab (PBP1502) TNF-alpha inhibitor | TNF | Phase 1 | Healthy Volunteers | Jun 2027 |
| Fondation Ophtalmologique Adolphe de Rothschild | etanercept TNF-alpha inhibitor | TNF | Phase 1 | Alzheimer Disease | Jun 2028 |
| Dong sheng Zhang | rmhTNF-NC Recombinant mutant human tumor necrosis factor | TNF | Phase 1 | Malignant Ascites | Jun 2028 |
| Kahr Medical | DSP107 SIRPα-4-1BBL bi-functional fusion protein; engages SIRPα on macrophages (CD172a) to block | SIRPA, TNF | Phase 1 | Advanced Solid Tumor | – |
Rheumatoid Arthritis (9) Crohn Disease (9) Ulcerative Colitis (5) Alcohol Use Disorder (3) Takayasu Arteritis (2) Melanoma Stage III (2) Locally Advanced Basal Cell Carcinoma (2) Malignant Ascites (2) Musculoskeletal Injury (2) Microscopic Colitis (2) Investigating the Importance of the Subjective Psychedelic Experience (2) Colitis (2)
antibody (11), small molecule (8), mixed (7), protein or peptide (1)
University Hospital, Strasbourg, France (2) Chia Tai Tianqing Pharmaceutical Group (1) Fondation Ophtalmologique Adolphe de Rothschild (1) National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland (1) Wayne State University (1) Prestige Biopharma (1) Philogen (1) Dong sheng Zhang (1) Kahr Medical (1) Connecticut Children's Medical Center (1) Memorial Sloan Kettering Cancer Center (1) London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) Assistance Publique - Hôpitaux de Paris (1) Sir Run Run Shaw Hospital (1) University of Calgary (1) Odense University Hospital (1) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) University of Pennsylvania (1) David Ware Branch (1) Taizhou Mabtech Pharmaceutical (1)
HTR2A (2) FKBP1A (2) SIRPA (1) IL6 (1) PDCD1LG1 (1) CNR1 (1) PLAT (1) IL12B (1) IL23A (1) ADRB2 (1) NR3C1 (1) PTGS2 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.